Clinical Trials on Recurrent C. Difficile Associated Diarrhea in New Zealand

Total 58 results

Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Genzyme, a Sanofi Company

Completed

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

Clostridium Difficile-Associated Diarrhea | Antibiotic-associated Diarrhea | Clostridium Enterocolitis | Clostridium Difficile Diarrhea | Antibiotic-associated Colitis

United States, Canada, United Kingdom, Puerto Rico
McMaster University

Completed

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT)

Infections | Diarrhea | Ventilator Associated Pneumonia | Antibiotic-associated Diarrhea | C-Difficile

Canada, United States, Saudi Arabia
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea (PUNCH CD)

Recurrent Clostridium Difficile Infection

United States
Astellas Pharma Europe B.V.
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (SUNSHINE)

Clostridium Difficile-associated Diarrhea (CDAD)

United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
Bio-K Plus International Inc.
Sprim Advanced Life Sciences

Suspended

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Pfizer

Active, not recruiting

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons. It Will Be Given Twice Over a Period of Time to Healthy Adults

Clostridoides Difficile Associated Disease

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Post Liver Transplant | Recurrent Chronic Hepatitis C Virus

United States, Spain, New Zealand, France, Germany
State University of New York at Buffalo

Withdrawn

Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy (c diff)

C. Difficile Infection

United States
Pfizer

Completed

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Clostridium Difficile Associated Disease

United States
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD2)

Enterocolitis Clostridium Difficile Recurrent

United States, Canada
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile Associated Disease

United States
Vedanta Biosciences, Inc.

Completed

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (CONSORTIUM)

Clostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection Recurrence

United States, Canada
Pfizer

Completed

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Clostridium Difficile Associated Disease

United States
Deinove

Recruiting

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Clostridium Difficile (C. Difficile)

United States, Canada
Memorial Sloan Kettering Cancer Center

Completed

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

Cancer | C. Difficile Infection

United States
Bausch Health Americas, Inc.

Completed

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea (ADVENT)

HIV Associated Diarrhea

United States, Puerto Rico
Maimonides Medical Center

Completed

Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin

Clostridium Difficle Colitis | Clostridium Difficle Associated Disease

United States
Summit Therapeutics
Wellcome Trust

Completed

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Clostridium Difficile Infection

United States, Canada
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Adiso Therapeutics

Completed

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

Clostridium Difficile Infection Recurrence

United States, Canada
Ferring Pharmaceuticals

Recruiting

REBYOTA™ Prospective Registry (ROAR)

Recurrence of Clostridium Difficile Infection

United States
Actelion

Completed

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea

Clostridium Difficile Infection

United States, Belgium, Israel, Argentina, Brazil, Canada, Chile, Croatia, Czechia, Greece, Hungary, Korea, Republic of, Romania, Slovakia
Sanofi Pasteur, a Sanofi Company

Completed

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Diarrhea | Clostridium Difficile Infection

United States
Actelion

Completed

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea

Clostridium Difficile Infection

United States, Australia, Brazil, Canada, France, Germany, Italy, Netherlands, Peru, Poland, Romania, Spain
Genzyme, a Sanofi Company

Terminated

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

Diarrhea | Enterocolitis, Pseudomembranous | Clostridium Difficile

United States
Cubist Pharmaceuticals LLC

Completed

Study of CB-183,315 in Participants With Clostridium Difficile Infection

Diarrhea | Clostridium Difficile Infection

United States, Canada
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
Rochester General Hospital

Terminated

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Clostridium Difficile Infection

United States
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Cirrhosis | Hepatitis B Infection | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Hepatocellular Carcinoma | Refractory Malignant Neoplasm | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7

United States
Seres Therapeutics, Inc.
Pharm-Olam International

Completed

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Clostridium Difficile Infection

United States
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings (SHARP-C)

Hepatitis C, Chronic

Australia
Institut Pasteur
University of Copenhagen; Institut Cochin

Completed

Study on the Association Between Vitamin C Deficiency and Diarrhea in Children (VITAL)

Diarrhea | Infantile

France, New Caledonia, Central African Republic
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Gilead Sciences

Completed

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Hepatocellular Carcinoma | Hepatitis C

United States, New Zealand, Spain
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Diarrhea | Fungal Infection | Neutropenia | Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Bacterial Infection | Acute Leukemias of Ambiguous Lineage | Musculoskeletal Complications | Untreated Childhood Acute Myeloid Leukemia...

United States, Canada
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

HIV Infection | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular... and other conditions

United States
Atara Biotherapeutics
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
National Institute of Diabetes and Digestive and...
Schering-Plough; Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation (LADR)

Hepatitis C

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
Atara Biotherapeutics
Memorial Sloan Kettering Cancer Center

Completed

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

United States
Roswell Park Cancer Institute

Completed

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States

Clinical Trials on Recurrent C. Difficile Associated Diarrhea in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations